Verici Dx plc (AIM: VRCI)

Market Cap	16.37M
Revenue (ttm)	3.43M
Net Income (ttm)	-3.81M
Shares Out	242.54M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,636
Open	6.65
Previous Close	6.75
Day's Range	6.50 - 6.70
52-Week Range	5.50 - 13.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 15, 2024

About Verici Dx

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 14
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VRCI

Financial Performance

Financial numbers in USD